8-K: Aspira Womens Health Appoints Brian Hungerford as CFO

Aspira Womens Health Inc. has appointed Brian Hungerford as its new Chief Financial Officer and Principal Accounting Officer, effective September 2, 2025.

Summary

• Aspira Womens Health Inc. (AWHL) has appointed Brian Hungerford, age 50, as its Chief Financial Officer (CFO) and Principal Accounting Officer, effective September 2, 2025.
• Mr. Hungerford replaces Julie Carrillo in these roles.
• He brings over 20 years of experience across various industries, including a previous role as CFO for Kiromic Biopharma, Inc.
• The appointment is made under a Master Services Agreement and Statement of Work with Hungerford Consulting LLC, where Mr. Hungerford is designated to provide full-time services as CFO.
• His compensation package includes an annual base salary of $300,000, payable semi-monthly.
• Mr. Hungerford is eligible for a target annual cash bonus of 35% of his base compensation, contingent on achieving performance goals set by management and the board.
• He will receive a grant of 100,000 non-qualified stock options (NSOs) with an exercise price equal to the closing stock price on the September 2, 2025 grant date.
• The stock options will vest 25% on September 2, 2026, with the remaining 75% vesting monthly over the subsequent 36 months.
• Severance provisions include 3 months of base salary if terminated without cause between 6 and 12 months of engagement, and 6 months of base salary if terminated without cause after 12 months.
• In the event of a termination without cause or for good reason within 12 months following a change of control, 100% of any unvested options will immediately vest.
• Mr. Hungerford is not considered an employee of Aspira Womens Health Inc. but an employee of Hungerford Consulting LLC, and is not eligible for company-sponsored employee benefits.
• He is subject to restrictive covenants including non-competition, non-solicitation of clients/vendors, and non-solicitation of employees for two years post-engagement, specifically in the gynecologic or women's health diagnostic devices or services business.

Sentiment

Score: 7

Explanation: The appointment of an experienced CFO is generally a positive development, indicating a focus on strengthening financial leadership and corporate governance. The structured compensation package with performance incentives is also a favorable aspect.

Positives

• The appointment of Brian Hungerford, with over 20 years of experience, brings seasoned financial leadership to the company.
• His prior experience as CFO for a biopharmaceutical R&D company aligns with the specialized nature of Aspira Womens Health Inc.'s business.
• The structured compensation package, including performance-based bonuses and stock options, incentivizes long-term performance and alignment with shareholder interests.

Risks

• The company relies on a consulting agreement for its CFO services, meaning Brian Hungerford is an employee of Hungerford Consulting LLC, not Aspira, which could introduce complexities regarding employment classification or direct control.
• The indemnification provided to Mr. Hungerford as an officer does not include separate or extended tail coverage following termination of services, potentially leaving him exposed to certain liabilities post-departure.
• The company's ability to retain Mr. Hungerford is subject to the terms of the consulting agreement, and his departure could disrupt financial operations and strategic initiatives.

Future Outlook

The company anticipates Brian Hungerford will fulfill the customary duties of a CFO for a publicly traded company, including strategic financial oversight and capital markets activities. His compensation structure, including stock options vesting over 37 months and performance-based bonuses, aligns his future incentives with the company's long-term performance and strategic goals. Specific bonus milestones for 2025 will be determined within 30 days of his start date.

Industry Context

The appointment of an experienced Chief Financial Officer is a standard practice for publicly traded companies, particularly those in specialized sectors like women's health diagnostics. This move aims to strengthen financial leadership and strategic planning, which is crucial for navigating the complex regulatory and market landscape of the healthcare industry.

Management Changes

Corporate Governance

Legal Proceedings

• The Master Services Agreement includes provisions for dispute resolution, starting with amicable efforts, followed by mediation in Connecticut, and then arbitration in Connecticut under the American Arbitration Association Rules.
• Both parties, including Brian Hungerford, irrevocably and unconditionally waive their right to trial by jury for any claim or cause of action arising out of the agreement.

Stakeholder Impact

• Shareholders: Benefit from the appointment of an experienced CFO, potentially leading to improved financial management and strategic decision-making. The stock option grant aligns the CFO's interests with shareholder value creation.
• Employees: The non-solicitation clause prevents the new CFO from enticing company employees to leave for two years post-engagement, helping to retain talent.
• Customers/Suppliers/Vendors: The non-solicitation clause protects the company's business relationships with its partners for two years post-engagement.

Next Steps

• Brian Hungerford will commence his duties as CFO and Principal Accounting Officer.
• Specific bonus milestones and objectives for 2025 will be determined jointly by the Board, CEO, and Mr. Hungerford within thirty days of his start date.
• The first tranche of 25% of Mr. Hungerford's stock options will vest on September 2, 2026, with the remainder vesting monthly over the subsequent 36 months.

Key Dates

Keywords

CFO appointment, Chief Financial Officer, Principal Accounting Officer, management change, executive compensation, stock options, severance, corporate governance, Aspira Womens Health, AWHL, biopharmaceutical, womens health